PPPablo Penaloza-MacMaster

Pablo Penaloza-MacMaster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Penaloza-MacMaster has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Tanushree Dangi

    Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    14 shared publications
  • Tanushree Dangi

    Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University , Chicago, IL

    12 shared publications
  • Sarah Sanchez

    Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

    9 shared publications
  • Justin M. Richner

    University of Illinois Chicago

    8 shared publications
  • Bakare Awakoaiye

    Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University , Chicago, IL

    5 shared publications
  • Nicole Palacio

    Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States

    5 shared publications

Latest Publications

  • Open Access

    Epitope Mapping and MHC Restriction of Next-Generation Tuberculosis Vaccine Antigens in Mice

    by Samuel J. Vidal, Alejandro A. Espinosa Perez, Ganad D. Neka, Aleisha M. G. Roberts, Yu Sun, Lili Benitez Angeles, Hannah I. Angulo Espinoza, Ellis A. Strutton, Esther R. Mbiwan, Jayeshbhai Chaudhari, et al.

    Background/Objectives: Classical major histocompatibility complex (MHC)-restricted T cells play essential roles in tuberculosis (TB) immunity. Characterizing the antigen targets, dominant epitopes, and MHC restriction of protective T-cell responses is important for understanding TB immunity and next-generation TB vaccine development. Methods: We recently used vaccine screening in mice to identify Rv1387 (PPE20), Rv0287 (EsxG), Rv1788 (PE18), and Rv1886c (Ag85B) as protective antigens, and in this paper, we characterized the T-cell responses to these antigens in mice. Results: We first identified the full repertoire of CD4 and CD8 T-cell epitopes in C57BL/6 and BALB/c mice. We further defined the MHC class I and II restriction of immunodominant epitopes, enabling the development and validation of tetramers for probing cognate T-cell responses. Finally, we used these tetramers to contrast lung mucosal T-cell phenotypes in the setting of Bacillus Calmette–Guérin (BCG) and mRNA vaccination. Conclusions: These results define the T-cell epitopes and MHC restriction of next-generation TB vaccine antigens and contribute reagents for studying TB T-cell immunity.

  • Open Access

    The Immune Landscape of Canine Soft Tissue Sarcomas as a Model for Human Soft Tissue Sarcomas

    by Regina Hayburn, Dongjun Chung, Arkobato Gupta, Shane Sills, Jennifer Donglan Wu, Andy Ambrus, Weiqing Jing, Juliana Ng, Pablo Penaloza-MacMaster, Aubrie Selmek, et al.

    Background/Objectives: Soft tissue sarcomas (STS) remain a therapeutic challenge due to their limited response to radiation and conventional chemotherapies. While recent advances in immunotherapy have improved outcomes in several cancers, these strategies have been largely disappointing in STS patients. Naturally occurring STS in dogs have been suggested as a spontaneous, immunocompetent model of human STS, but further characterization of its tumor immune microenvironment is needed to validate its relevance. This study aimed to identify the shared immune-related components of canine and human STS and to determine how these factors influence the tumor biology, progression, and prognosis. Results: Data from 75 dogs with STS was analyzed. In addition, we characterized the tumor immune microenvironment using immunohistochemistry and compared gene expression between canine and human STS. Progression-free survival and time to metastasis was significantly longer in castrated males in comparison to females. In addition, dogs with appendicular tumors had better progression- and recurrence-free survival, whereas tumor recurrence following surgical excision was associated with a shorter time to metastasis. Immunohistochemistry revealed infiltration of CD204+ cells in most of the tumors examined, and disease-free intervals were shorter in dogs with tumors exhibiting FOXP3+ cell infiltration. Gene expression profiling demonstrated similarities between canine STS and human undifferentiated pleomorphic sarcomas, with MYC dysregulation emerging as a poor prognostic indicator for dogs. Conclusions: The comparative analysis between the human and canine STS microenvironment offers a valuable insight into the clinical behavior and immune landscape of canine STS, underscoring its potential as a relevant preclinical model for the translation and development of future immunotherapies.


  • Open Access

    Development of a cross-protective common cold coronavirus vaccine

    by Tanushree Dangi, Shiyi Li, Pablo Penaloza-MacMaster

    Common cold coronaviruses, such as OC43 and HKU1, typically cause mild respiratory infections in healthy people. However, they can lead to severe illness in high-risk groups, including immunocompromised individuals and older adults. Currently, there is no clinically approved vaccine to prevent infection by common cold coronaviruses. Here, we developed an mRNA vaccine expressing a stabilized spike protein derived from OC43 coronavirus and tested its efficacy in different challenge models in C57BL/6 mice. This novel OC43 vaccine elicited OC43-specific immune responses, as well as cross-reactive immune response against other embecoviruses, including HKU1 and mouse hepatitis virus (MHV-A59). Interestingly, this OC43 vaccine protected mice not only against a lethal OC43 infection but also against a distant embecovirus, MHV-A59. These findings provide insights for the development of common cold coronavirus vaccines, demonstrating their potential to protect against various coronaviruses. IMPORTANCE: Human coronaviruses like OC43 cause disease in vulnerable populations, yet no approved vaccines exist. We developed an mRNA vaccine targeting the OC43 spike protein that protects mice not only against homologous OC43 challenges but also against the distantly related embecovirus MHV-A59. These findings demonstrate the feasibility of a single vaccine conferring broad protection across multiple coronaviruses within the same subgenus, advancing strategies for pan-coronavirus vaccine development.


  • Open Access

    Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy

    by Bakare Awakoaiye, Shiyi Li, Sarah Sanchez, Tanushree Dangi, Nahid Irani, Laura Arroyo, Gabriel Arellano, Shadi Mohammadabadi, Malika Aid, Pablo Penaloza-MacMaster

    Despite the widespread use of adenovirus, mRNA, and protein-based vaccines during the COVID-19 pandemic, their relative immunological profiles and protective efficacies remain incompletely defined. Here, we compared antigen kinetics, innate and adaptive immune responses, and protective efficacy following Ad5, mRNA, and protein vaccination in mice. Ad5 induced the most sustained antigen expression, but mRNA induced the most potent IFN responses, associated with robust antigen presentation and costimulation. Unlike Ad5 vaccines, which were hindered by preexisting vector immunity, mRNA vaccines retained efficacy after repeated use. As a single-dose regimen, Ad5 vaccines elicited higher immune responses. However, as a prime-boost regimen, and particularly in Ad5 seropositive mice, mRNA vaccines were more immunogenic than the other vaccine platforms. These findings highlight strengths of each vaccine platform and underscore the importance of host serostatus in determining optimal vaccine performance.


  • Open Access

    Recombinant Orf viral vectors: A novel vaccine platform

    by Pablo Penaloza-MacMaster

  • Open Access

    A viral vector prime and protein boost vaccine regimen elicits higher binding antibody titers than a homologous viral vector prime-boost regimen

    by Bakare Awakoaiye, Tanushree Dangi, Pablo Penaloza-MacMaster

    (SARS-CoV-2) has infected a large fraction of the human population. Currently, most individuals have developed immunity either through vaccination or natural infection. Despite this, SARS-CoV-2 booster immunizations are still recommended to reduce the risk of reinfections, but there is still limited understanding of how different booster vaccine platforms influence antibody responses. We conducted immunological studies in mice to evaluate the boosting effects of different vaccine platforms on antibody responses. C57BL/6 mice were first primed with an adenovirus serotype 5 (Ad5) vector vaccine expressing the SARS-CoV-2 spike protein. The mice were then boosted with the same Ad5-based vaccine (homologous boosting) or with a protein-based vaccine (heterologous boosting). Interestingly, the heterologous regimen (Ad5 prime/Protein boost) elicited higher binding antibody responses, relative to the homologous regimen (Ad5 prime/Ad5 boost). Similar potentiation of antibody titers was reported when mice were primed with poxvirus or rhabdovirus vectors and then boosted with protein. These findings highlight a potential advantage of protein booster immunizations to potentiate humoral immunity.